We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Agronomics Limited | LSE:ANIC | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -2.08% | 4.70 | 4.70 | 4.80 | 4.75 | 4.75 | 4.75 | 623,826 | 16:35:19 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investors, Nec | 30.88M | 22.37M | 0.0222 | 2.14 | 48.45M |
From Oct 2019 to Oct 2024
TIDMPEBI
RNS Number : 4243W
Port Erin Biopharma Investments Ltd
25 January 2013
Port Erin Biopharma Investments Limited ("the Company")
Net Asset Value calculation to 31(st) December 2012
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2012 was 9.50 pence per share, including un-invested cash of GBP101,241. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a small decrease from the previous valuation of 9.63 pence per share, which included un-invested cash of GBP329,708. The revenue reserve has increased substantially following the deduction of listing expenses from the share premium account and still represents a return of over 16.0% on investments after operating costs. Indeed, if the NAV valuation were to be published today, the NAV per share would approach 10.4 pence."
Hot Features
Premium
Unaudited
15 September 2011
to 31 December 2012
GBP
Fixed Assets
Investments 3,031,135
Current Assets
Debtors: amounts owing 9,035
Un-invested cash 101,241
Current Liabilities
Creditors: amounts due (7,292)
3,134,119
Capital and Reserves
Share Capital 33
Share Premium 2,699,011
Capital reserve - realised 0
Capital reserve - unrealised 0
Revenue reserve 435,075
3,134,119
Shares in Issue 33,000,000
Net Asset Value per share 9.50 pence
--- ENDS ---
Portfolio Details
Investments Schedule at 31st December 2012 Valuation GBP Portfolio %
Summit Corporation plc GBP269,166.87 8.88%
Cytox Limited GBP200,000.00 6.60%
Gilead Sciences Inc. GBP195,452.13 6.45%
Synergy Pharmaceuticals Inc. GBP182,814.82 6.03%
Plethora Solutions Holdings plc GBP180,000.00 5.94%
Celgene Inc. GBP141,125.68 4.66%
Astellas Pharma Inc. GBP140,762.00 4.64%
Arrowhead Resources GBP135,419.97 4.47%
TrovaGene Inc. GBP127,845.13 4.22%
Abbott Laboratories GBP117,762.25 3.89%
Pfizer Inc. GBP114,835.48 3.79%
----------------- ------------
GBP1,805,184.33 59.55%
Aggregate value of remaining holdings below 3% of total portfolio GBP1,225,950.25 40.45%
TOTAL INVESTMENTS GBP3,031,134.58 100.00%
------------------------------------------------------------------- ----------------- ------------
For further information, please contact:
Port Erin Biopharma Libertas Capital Corporate Peterhouse Capital Investments Ltd Finance Limited Limited The Company Nomad Broker Denham Eke Sandy Jamieson Jon Levinson +44 162 463 9396 +44 207 569 9650 +44 207 562 3350
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVLLFFELRIEFIV
1 Year Agronomics Chart |
1 Month Agronomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
